[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "First peer-reviewed vaccine evidence", "description": "V Day, good start\n\nThree-and-a-half, 975 doses\n\nOver-80s and NHS and care home staff\n\n70 hospital hubs\n\n800,000 doses\n\nOne million from Belgium by next week\n\n2020, 5 million doses\n\nTwo adverse reactions\n\nAnaphylactoid \n\nBoth shortly after\n\nBoth fine\n\nBoth history of serious allergies and carry adrenalin pens \n\nSevere allergic patents not in trials\n\nProfessor Stephen Powis\n\nAs is common with new vaccines, the MHRA have advised on a precautionary basis that people with a significant history of allergic reactions do not receive this vaccination after two people with a history of significant allergic reactions responded adversely\n\nDr June Raine, (MHRA)\n\nOnly right to take this step now that we've had this experience\n\n\nFirst peer-reviewed vaccine evidence\n\nSafety and efficacy of the ChAdOx1 nCoV-19 vaccine\n(AZD1222) against SARS-CoV-2: an interim analysis of\nfour randomised controlled trials in Brazil, South Africa,\nand the UK\n\nhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext\n\nOxford University\n\nReplication-deficient chimpanzee adenoviral vector\n\nContaining the SARS-CoV-2 structural surface\nglycoprotein antigen (spike protein; nCoV-19) gene.\n\nEvaluated the safety and efficacy\n\nMethods\n\nFour ongoing blinded, randomised, controlled trials\n\nUK, Brazil, and South Africa\n\nParticipants aged 18 +\n\nRandomly assigned, 1:1\n\nVaccine or control (meningococcal group conjugate vaccine or saline)\n\nVaccine group\n\nTwo doses containing 5\u2008\u00d7\u20081010 viral particles (standard dose)\n\nA subset in the UK trial, half dose first (low dose) and a standard dose second\n\nInfections recorded more than 14 days after a second dose\n\nData cutoff Nov 4, 2020\n\nApril 23 to Nov 4, 2020\n\n23,848 participants were enrolled\n\n11,636 participants (7548 in the UK, 4088 in Brazil), interim primary efficacy analysis\n\nThere were 131 cases of symptomatic COVID-19 in\n\nLD/SD or SD/SD recipients combined\n\nVaccine group\n\nN = 5,807\n\n30 cases\n\nControl group\n\nN = 5,829\n\n101 cases\n\nResulting in overall vaccine efficacy of 70.4%\n\nSD/SD group\n\nVaccine group, 27 cases \n\nControl group, 71 cases\n\nVaccine efficacy was 62\u00b71%\n\nUK, 60\u00b73% efficacy\n\nBrazil, 64\u00b72% efficacy\n\nLD/SD goup\n\nVaccine group, 3 cases from 1,367\n\nControl group 30 cases from 1,374\n\nVaccine efficacy was 90%\n\nLD/HD group had less asymptomatic infections\n\nSix week gap may also help\n\nImplications for ongoing contagion\n\nFrom 21 days after the first dose\n\nTen cases hospitalised for COVID-19, two classified as severe, one death\n\nVaccine efficacy 100%\n\nSafety\n\n74,341 person-months of safety follow-up\n\n175 severe adverse events occurred in 168 participants\n\n84 events in vaccine group\n\n91 in the control group\n\nThree events were classified as possibly related to a vaccine\n\nOne in the vaccine group, one in the control group", "link": "https://www.youtube.com/watch?v=5fXn1PCU2E8", "date_published": "2020-12-09 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]